Entera Bio Ltd. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.


Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending June 29, 2020 was $605 Thousand (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) decreased by -0.33%
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $605 Thousand (a -7.07% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2018 was $651 Thousand (a -0.46% decrease from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of Entera Bio Ltd.

Most recent Goodwill and Intangible Assets (Total)of ENTX including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of Entera Bio Ltd.

Entera Bio Ltd. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.61 $0.61
2019 $0.61 $0.61 $0.62 $0.64 $0.61
2018 $0.65 $0.0 $0.0 $0.0 $0.65
2017 $0.65 $0.65

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.